Using disease-modifying treatments shortly prior to or during pregnancy does not seem to increase the risk of neurodevelopmental disorders in exposed children, according to a real-world study of mothers with multiple sclerosis (MS). Still, sphingosine-1-phosphate (S1P) receptor modulators, which include therapies such as Gilenya (fingolimod), Mayzent (siponimod), and Ponvory (ponesimod), were linked to an increased […]
The post MS treatment during pregnancy found safe for babies’ brain growth appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com